LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 3 of 15: Cell count and relative growth within biological replicate 3. - Dataset (ID:20239)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | TGX221 | 10.0 | uM | LJP5 | 1 | H19 | 72 | hr | 1401 | 3726 | 4223 | 0.8823 | 0.8238 |
| SK-BR-3 | TGX221 | 10.0 | uM | LJP5 | 2 | H19 | 72 | hr | 1401 | 3787 | 4223 | 0.8967 | 0.8454 |
| SK-BR-3 | TGX221 | 10.0 | uM | LJP5 | 3 | H19 | 72 | hr | 1401 | 3884 | 4223 | 0.9197 | 0.8798 |
| SK-BR-3 | Torin1 | 10.0 | uM | LJP6 | 1 | O13 | 72 | hr | 1401 | 1396 | 4223 | 0.3306 | -0.0020 |
| SK-BR-3 | Torin1 | 10.0 | uM | LJP6 | 2 | O13 | 72 | hr | 1401 | 1316 | 4223 | 0.3116 | -0.0303 |
| SK-BR-3 | Torin1 | 10.0 | uM | LJP6 | 3 | O13 | 72 | hr | 1401 | 1208 | 4223 | 0.2861 | -0.0686 |
| SK-BR-3 | Torin2 | 10.0 | uM | LJP5 | 1 | I19 | 72 | hr | 1401 | 938 | 4223 | 0.2221 | -0.1643 |
| SK-BR-3 | Torin2 | 10.0 | uM | LJP5 | 2 | I19 | 72 | hr | 1401 | 958 | 4223 | 0.2269 | -0.1572 |
| SK-BR-3 | Torin2 | 10.0 | uM | LJP5 | 3 | I19 | 72 | hr | 1401 | 1246 | 4223 | 0.2950 | -0.0551 |
| SK-BR-3 | Tozasertib | 10.0 | uM | LJP5 | 1 | B13 | 72 | hr | 1401 | 1503 | 4223 | 0.3559 | 0.0360 |
| SK-BR-3 | Tozasertib | 10.0 | uM | LJP5 | 2 | B13 | 72 | hr | 1401 | 1644 | 4223 | 0.3893 | 0.0859 |
| SK-BR-3 | Tozasertib | 10.0 | uM | LJP5 | 3 | B13 | 72 | hr | 1401 | 1541 | 4223 | 0.3649 | 0.0494 |
| SK-BR-3 | Trametinib | 10.0 | uM | LJP5 | 1 | P19 | 72 | hr | 1401 | 3293 | 4223 | 0.7798 | 0.6704 |
| SK-BR-3 | Trametinib | 10.0 | uM | LJP5 | 2 | P19 | 72 | hr | 1401 | 3536 | 4223 | 0.8373 | 0.7565 |
| SK-BR-3 | Trametinib | 10.0 | uM | LJP5 | 3 | P19 | 72 | hr | 1401 | 4014 | 4223 | 0.9505 | 0.9259 |
| SK-BR-3 | TWS119 | 10.0 | uM | LJP5 | 1 | M01 | 72 | hr | 1401 | 847 | 4223 | 0.2006 | -0.1965 |
| SK-BR-3 | TWS119 | 10.0 | uM | LJP5 | 2 | M01 | 72 | hr | 1401 | 1614 | 4223 | 0.3822 | 0.0753 |
| SK-BR-3 | TWS119 | 10.0 | uM | LJP5 | 3 | M01 | 72 | hr | 1401 | 2121 | 4223 | 0.5022 | 0.2550 |
| SK-BR-3 | Vemurafenib | 10.0 | uM | LJP5 | 1 | C13 | 72 | hr | 1401 | 3922 | 4223 | 0.9287 | 0.8933 |
| SK-BR-3 | Vemurafenib | 10.0 | uM | LJP5 | 2 | C13 | 72 | hr | 1401 | 3668 | 4223 | 0.8686 | 0.8033 |
| SK-BR-3 | Vemurafenib | 10.0 | uM | LJP5 | 3 | C13 | 72 | hr | 1401 | 3192 | 4223 | 0.7558 | 0.6346 |
| SK-BR-3 | Withaferin A | 10.0 | uM | LJP5 | 1 | G13 | 72 | hr | 1401 | 1080 | 4223 | 0.2557 | -0.1140 |
| SK-BR-3 | Withaferin A | 10.0 | uM | LJP5 | 2 | G13 | 72 | hr | 1401 | 1006 | 4223 | 0.2382 | -0.1402 |
| SK-BR-3 | Withaferin A | 10.0 | uM | LJP5 | 3 | G13 | 72 | hr | 1401 | 968 | 4223 | 0.2292 | -0.1537 |
| SK-BR-3 | Withaferin A | 10.0 | uM | LJP6 | 1 | G13 | 72 | hr | 1401 | 1261 | 4223 | 0.2986 | -0.0498 |